Tissue transglutaminase in alzheimer's disease: Involvement in pathogenesis and its potential as a therapeutic target

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S289-S303

  Wilhelmus, Micha M M ^a   De Jager, Mieke ^a   Bakker, Erik N T P ^b   Drukarch, Benjamin ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; amyloid ; cerebral amyloid angiopathy; crosslinking; neurofibrillary tangles; senile plaques; therapy; tissue transglutaminase

Indexed keywords

6 (GAMMA GLUTAMYL)LYSINE; AMYLOID; PROTEIN AGGREGATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; AMYLOID BETA PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROLEPTIC AGENT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

ALZHEIMER DISEASE; COMPLEX FORMATION; CONFERENCE PAPER; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; HUNTINGTON CHOREA; PATHOGENESIS; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; GTP-BINDING PROTEINS; HUMANS; TRANSGLUTAMINASES;

EID: 84920617427     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132492     Document Type: Conference Paper

References (132)

1. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
2. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ (1991) A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678.
3. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, et al. (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11, 1593-1597.
4. Trojanowski JQ, Lee VM (1995) Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: Focusing on phosphatases. FASEB J 9, 1570-1576.
5. Kowall NW, Kosik KS (1987) Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann Neurol 22, 639-643.
6. Greenberg CS, Birckbichler PJ, Rice RH (1991) Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues. FASEB J 5, 3071-3077.
7. Lorand L, Graham RM (2003) Transglutaminases: Crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4, 140-156.
8. Folk JE, Finlayson JS (1977) The epsilon-(gammaglutamyl) lysine crosslink and the catalytic role of transglutaminases. Adv Protein Chem 31, 1-133.
9. Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM(2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 100, 2047-2052.
10. Igarashi S, Koide R, Shimohata T, Yamada M, Hayashi Y, Takano H, Date H, Oyake M, Sato T, Sato A, Egawa S, Ikeuchi T, Tanaka H, Nakano R, Tanaka K, Hozumi I, Inuzuka T, Takahashi H, Tsuji S (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 18, 111-117.
11. Kahlem P, Green H, Djian P (1998) Transglutaminase action imitates Huntington's disease: Selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1, 595-601.
12. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, BealMF, Hersch SM, Ferrante RJ (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22, 8942-8950.
13. Karpuj MV, Becher MW, Steinman L (2002) Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int 40, 31-36.
14. Selkoe DJ (2002) Introducing transglutaminase into the study of Alzheimer's disease. A personal look back. Neurochem Int 40, 13-16.
15. Wilhelmus MM, van Dam AM, Drukarch B (2008) Tissue transglutaminase: A novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur J Pharmacol 585, 464-472.
16. Wilhelmus MM, de JM, Drukarch B (2012) Tissue transglutaminase: A novel therapeutic target in cerebral amyloid angiopathy. Neurodegener Dis 10, 317-319.
17. Bartus RT, Dean RL, III, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-414.
18. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45, 583-595.
19. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nat Rev Drug Discov 5, 160-170.
20. Hu NW, Klyubin I, Anwyl R, Rowan MJ (2009) GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci USA 106, 20504-20509.
21. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM,Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
22. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227-1235.
23. Wilkinson D, Wirth Y, Goebel C (2013) Memantine in patients with moderate to severe Alzheimer's disease: Metaanalyses using realistic definitions of response. Dement Geriatr Cogn Disord 37, 71-85.
24. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P (2013) Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase IIIantibody trials: A report from the EU/US/CTAD Task Force. Alzheimers Dement 9, 438-444.
25. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Forster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S,Wietek S, Farlow M, Jessen F (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: A phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12, 233-243.
26. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, DumortierT, MaguireRP, BlennowK, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11, 597-604.
27. Doody RS, Raman R, FarlowM, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R (2013) A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369, 341-350.
28. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM (2012) Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69, 1430-1440.
29. Mullane K, Williams M (2013) Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85, 289-305.
30. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373, 523-527.
31. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.
32. Glabe CG (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging 27, 570-575.
33. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
34. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
35. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG (2004) Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 24, 3801-3809.
36. Mc Donald JM, Savva GM, Brayne C,WelzelAT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133, 1328-1341.
37. Casadio R, Polverini E, Mariani P, Spinozzi F, Carsughi F, Fontana A, Polverino de LP, Matteucci G, Bergamini CM (1999) The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur J Biochem 262, 672-679.
38. Bergamini CM, Dean M, Matteucci G, Hanau S, Tanfani F, Ferrari C, Boggian M, Scatturin A (1999) Conformational stability of human erythrocyte transglutaminase. Patterns of thermal unfolding at acid and alkaline pH. Eur J Biochem 266, 575-582.
39. Bergamini CM, Signorini M (1990) In vivo inactivation of transglutaminase during the acute acrylamide toxic syndrome in the rat. Experientia 46, 278-281.
40. Iismaa SE, Wu MJ, Nanda N, Church WB, Graham RM (2000) GTP binding and signaling by Gh/transglutaminase II involves distinct residues in a unique GTP-binding pocket. J Biol Chem 275, 18259-18265.
41. Lai TS, Bielawska A, Peoples KA, Hannun YA, Greenberg CS (1997) Sphingosylphosphocholine reduces the calcium ion requirement for activating tissue transglutaminase. J Biol Chem 272, 16295-16300.
42. Lai TS, Hausladen A, Slaughter TF, Eu JP, Stamler JS, Greenberg CS (2001) Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40, 4904-4910.
43. Lorand L, Conrad SM (1984) Transglutaminases. Mol Cell Biochem 58, 9-35.
44. Gaudry CA, Verderio E, Aeschlimann D, Cox A, Smith C, Griffin M (1999) Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain. J Biol Chem 274, 30707-30714.
45. Upchurch HF, Conway E, Patterson MK Jr, Birckbichler PJ, MaxwellMD(1987) Cellular transglutaminase has affinity for extracellular matrix. In Vitro Cell Dev Biol 23, 795-800.
46. Jandu SK, Webb AK, Pak A, Sevinc B, Nyhan D, Belkin AM, Flavahan NA, Berkowitz DE, Santhanam L (2013) Nitric oxide regulates tissue transglutaminase localization and function in the vasculature. Amino Acids 44, 261-269.
47. Zemskov EA, Mikhailenko I, Strickland DK, Belkin AM (2007) Cell-surface transglutaminase undergoes internalization and lysosomal degradation: An essential role for LRP1. J Cell Sci 120, 3188-3199.
48. Wilhelmus MM, Otte-Holler I, van Triel JJ, Veerhuis R, Maat-Schieman ML, Bu G, de Waal RM, Verbeek MM(2007) Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 171, 1989-1999.
49. Jones RA, Nicholas B, Mian S, Davies PJ, GriffinM(1997) Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci 110(Pt 19), 2461-2472.
50. Mosher DF (1984) Cross-linking of fibronectin to collagenous proteins. Mol Cell Biochem 58, 63-68.
51. Kleman JP, Aeschlimann D, Paulsson M, van derRM(1995) Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Biochemistry 34, 13768-13775.
52. Aeschlimann D, Thomazy V (2000) Protein crosslinking in assembly and remodelling of extracellular matrices: The role of transglutaminases. Connect Tissue Res 41, 1-27.
53. Martinez J, Rich E, Barsigian C (1989) Transglutaminasemediated cross-linking of fibrinogen by human umbilical vein endothelial cells. J Biol Chem 264, 20502-20508.
54. Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS (1988) Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 157, 115-120.
55. Akimov SS, Belkin AM (2001) Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98, 1567-1576.
56. Balklava Z,Verderio E, Collighan R, Gross S, Adams J, Griffin M (2002) Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: The active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 277, 16567-16575.
57. Kim SY, Grant P, Lee JH, Pant HC, Steinert PM (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol Chem 274, 30715-30721.
58. Wilhelmus MM, Grunberg SC, Bol JG, van Dam AM, Hoozemans JJ, Rozemuller AJ, Drukarch B (2009) Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol 19, 612-622.
59. Wilhelmus MM, Verhaar R, Bol JG, van Dam AM, Hoozemans JJ, Rozemuller AJ, Drukarch B (2011) Novel role of transglutaminase 1 in corpora amylacea formation? Neurobiol Aging 32, 845-856.
60. Lesort M, Attanavanich K, Zhang J, Johnson GV (1998) Distinct nuclear localization and activity of tissue transglutaminase. J Biol Chem 273, 11991-11994.
61. Verhaar R, Drukarch B, Bol JG, Jongenelen CA, Musters RJ, Wilhelmus MM (2012) Increase in endoplasmic reticulumassociated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease. Neurobiol Dis 45, 839-850.
62. Wilhelmus MM, Verhaar R, Andringa G, Bol JG, Cras P, Shan L, Hoozemans JJ, Drukarch B (2011) Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol 21, 130-139.
63. Bailey CD, JohnsonGV(2004) Developmental regulation of tissue transglutaminase in the mouse forebrain. J Neurochem 91, 1369-1379.
64. Maccioni RB, SeedsNW(1986) Transglutaminase and neuronal differentiation. Mol Cell Biochem 69, 161-168.
65. Mahoney SA, Wilkinson M, Smith S, Haynes LW (2000) Stabilization of neurites in cerebellar granule cells by transglutaminase activity: Identification of midkine and galectin-3 as substrates. Neuroscience 101, 141-155.
66. Singh US, Pan J, Kao YL, Joshi S, Young KL, Baker KM (2003)Tissue transglutaminase mediates activation of RhoA andMAPkinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem 278, 391-399.
67. Tucholski J, Lesort M, Johnson GV (2001) Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience 102, 481-491.
68. Zhang J, Lesort M, Guttmann RP, Johnson GV (1998) Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J Biol Chem 273, 2288-2295.
69. Johnson GV, Cox TM, Lockhart JP, Zinnerman MD, Miller ML, Powers RE (1997) Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 751, 323-329.
70. Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G (2002) Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease. Neurobiol Dis 11, 106-110.
71. Nemes Z, Fesus L, Egerhazi A, Keszthelyi A, Degrell IM (2001) N(epsilon)(gamma-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia. Neurobiol Aging 22, 403-406.
72. Wang DS, Uchikado H, Bennett DA, Schneider JA,Mufson EJ, Wu J, Dickson DW (2008) Cognitive performance correlates with cortical isopeptide immunoreactivity as well as Alzheimer type pathology. J Alzheimers Dis 13, 53-66.
73. Zhang W, Johnson BR, Suri DE, Martinez J, Bjornsson TD (1998) Immunohistochemical demonstration of tissue transglutaminase in amyloid plaques. Acta Neuropathol 96, 395-400.
74. Dudek SM, Johnson GV (1994) Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res 651, 129-133.
75. Ho GJ, Gregory EJ, Smirnova IV, Zoubine MN, Festoff BW (1994) Cross-linking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Lett 349, 151-154.
76. Schmid AW, Condemi E, Tuchscherer G, Chiappe D, Mutter M, Vogel H, Moniatte M, Tsybin YO (2011) Tissue transglutaminase-mediated glutamine deamidation of beta-amyloid peptide increases peptide solubility, whereas enzymatic cross-linking and peptide fragmentation may serve as molecular triggers for rapid peptide aggregation. J Biol Chem 286, 12172-12188.
77. Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, Li Z, Walz T (2008) Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem 283, 16790-16800.
78. Wakshlag JJ, Antonyak MA, Boehm JE, Boehm K, Cerione RA (2006) Effects of tissue transglutaminase on betaamyloid1-42-induced apoptosis. Protein J 25, 83-94.
79. Curro M, Ferlazzo N, Condello S, Caccamo D, Ientile R (2010) Transglutaminase 2 silencing reduced the betaamyloid-effects on the activation of human THP-1 cells. Amino Acids 39, 1427-1433.
80. Selkoe DJ, Abraham C, Ihara Y (1982) Brain transglutaminase: In vitro crosslinking of human neurofilament proteins into insoluble polymers. Proc Natl Acad Sci USA 79, 6070-6074.
81. Selkoe DJ, Ihara Y, Salazar FJ (1982) Alzheimer's disease: Insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Science 215, 1243-1245.
82. Appelt DM, Kopen GC, Boyne LJ, Balin BJ (1996) Localization of transglutaminase in hippocampal neurons: Implications for Alzheimer's disease. J Histochem Cytochem 44, 1421-1427.
83. Norlund MA, Lee JM, Zainelli GM, Muma NA (1999) Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res 851, 154-163.
84. Miller CC, Anderton BH (1986) Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease. J Neurochem 46, 1912-1922.
85. Lesort M, Tucholski J, Miller ML, Johnson GV (2000) Tissue transglutaminase: A possible role in neurodegenerative diseases. Prog Neurobiol 61, 439-463.
86. Dudek SM, Johnson GV (1993) Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J Neurochem 61, 1159-1162.
87. Tucholski J, Kuret J, Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: Possible functional and metabolic effects of polyamination. J Neurochem 73, 1871-1880.
88. Murthy SN,Wilson JH, Lukas TJ, Kuret J, Lorand L (1998) Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase. J Neurochem 71, 2607-2614.
89. Citron BA, Suo Z, SantaCruz K, Davies PJ, Qin F, Festoff BW (2002) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40, 69-78.
90. Wilhelmus MM, de JM, Rozemuller AJ, Breve J, Bol JG, Eckert RL, Drukarch B (2012) Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies. J Pathol 226, 132-142.
91. Singer SM, Zainelli GM, Norlund MA, Lee JM, Muma NA (2002) Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem Int 40, 17-30.
92. Nemes Z, Devreese B, Steinert PM, Van BJ, Fesus L (2004) Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J 18, 1135-1137.
93. Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, Muma NA (2003) Transglutaminase activity, protein, andmRNAexpression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol 62, 173-184.
94. Halverson RA, Lewis J, Frausto S, Hutton M, Muma NA (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25, 1226-1233.
95. de JM, van der WB, Schul E, Bol JG, van Duinen SG, Drukarch B, Wilhelmus MM (2013) Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy. Neurobiol Aging 34, 1159-1169.
96. LeeZW,Kwon SM, KimSW,Yi SJ, Kim YM, Ha KS (2003) Activation of in situ tissue transglutaminase by intracellular reactive oxygen species. Biochem Biophys Res Commun 305, 633-640.
97. Johnson GV, LeShoure R Jr (2004) Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity. J Neurosci Methods 134, 151-158.
98. KarpujMV, BecherMW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, SteinmanL(2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8, 143-149.
99. Verderio E, Nicholas B, Gross S, Griffin M (1998) Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: Effects on the processing of fibronectin, cell attachment, and cell death. Exp Cell Res 239, 119-138.
100. Lesort M, Lee M, Tucholski J, Johnson GV (2003) Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 278, 3825-3830.
101. Lai TS, Slaughter TF, Peoples KA, Hettasch JM, Greenberg CS (1998) Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes. Identification of distinct binding sites for Mg-GTP and Mg-ATP. J Biol Chem 273, 1776-1781.
102. Aeschlimann D, Paulsson M (1994) Transglutaminases: Protein cross-linking enzymes in tissues and body fluids. Thromb Haemost 71, 402-415.
103. Case A, Stein RL (2007) Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry 46, 1106-1115.
104. Duval E, Case A, Stein RL, Cuny GD (2005) Structureactivity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett 15, 1885-1889.
105. Bergamini CM (1988) GTP modulates calcium binding and cation-induced conformational changes in erythrocyte transglutaminase. FEBS Lett 239, 255-258.
106. de MP, Marrano C, Keillor JW (2002) Synthesis of dipeptide-bound epoxides and alpha,beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg Med Chem 10, 355-360.
107. Folk JE, Cole PW (1966) Identification of a functional cysteine essential for the activity of guinea pig liver transglutaminase. J Biol Chem 241, 3238-3240.
108. Tso JY, Bower SG, Zalkin H (1980) Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). J Biol Chem 255, 6734-6738.
109. Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P, Omary B, Rich KM, Khosla C (2005) Chemistry and biology of dihydroisoxazole derivatives: Selective inhibitors of human transglutaminase 2. Chem Biol 12, 469-475.
110. Watts RE, Siegel M, Khosla C (2006) Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 49, 7493-7501.
111. Killackey JJ, Bonaventura BJ, Castelhano AL, Billedeau RJ, Farmer W, DeYoung L, Krantz A, Pliura DH (1989) A new class of mechanism-based inhibitors of transglutaminase enzymes inhibits the formation of cross-linked envelopes by human malignant keratinocytes. Mol Pharmacol 35, 701-706.
112. Pardin C, Gillet SM, Keillor JW (2006) Synthesis and evaluation of peptidic irreversible inhibitors of tissue transglutaminase. Bioorg Med Chem 14, 8379-8385.
113. Halim D, Caron K, Keillor JW (2007) Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors. Bioorg Med Chem Lett 17, 305-308.
114. Marrano C, de MP, Gagnon P, Lapierre D, Gravel C, Keillor JW (2001) Synthesis and evaluation of novel dipeptidebound 1,2,4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg Med Chem 9, 3231-3241.
115. Marrano C, de MP, Keillor JW (2001) Evaluation of novel dipeptide-bound alpha,beta-unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg Med Chem 9, 1923-1928.
116. Bruce SE, Bjarnason I, Peters TJ (1985) Human jejunal transglutaminase: Demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin Sci (Lond) 68, 573-579.
117. Hausch F, Halttunen T, Maki M, Khosla C (2003) Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem Biol 10, 225-231.
118. Verhaar R, Jongenelen CA, Gerard M, Baekelandt V, van Dam AM, Wilhelmus M, Drukarch B (2011) Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem Int 58, 785-793.
119. Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger SM, Stern AM (1994) Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: Mechanism of factor XIIIa inactivation. Biochemistry 33, 10109-10119.
120. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Rispo A, Griffin M, Issekutz T, Quaratino S, Londei M (2005) Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 129, 1400-1413.
121. Barsigian C, Stern AM, Martinez J (1991) Tissue (type II) transglutaminase covalently incorporates itself, fibrinogen, or fibronectin into high molecular weight complexes on the extracellular surface of isolated hepatocytes. Use of 2-[(2-oxopropyl)thio] imidazolium derivatives as cellular transglutaminase inactivators. J Biol Chem 266, 22501-22509.
122. Matlung HL, VanBavel E, van den Akker J, de Vries CJ, Bakker EN (2010) Role of transglutaminases in cuffinduced atherosclerotic lesion formation in femoral arteries of ApoE3 Leiden mice. Atherosclerosis 213, 77-84.
123. Matlung HL, Neele AE, Groen HC, van GK, Tuna BG, van WA, de VJ, Wentzel JJ, Hoogenboezem M, van Buul JD, VanBavel E, Bakker EN (2012) Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress. Atherosclerosis 224, 355-362.
124. van den Akker J,VanBavel E, van GR, Matlung HL, Guvenc TB, Janssen GM, van Veelen PA, Boelens WC, DeMey JG, Bakker EN (2011) The redox state of transglutaminase 2 controls arterial remodeling. PLoS One 6, e23067.
125. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26, 2563-2573.
126. Matic I, Sacchi A, Rinaldi A, Melino G, Khosla C, Falasca L, PiacentiniM(2010) Characterization of transglutaminase type II role in dendritic cell differentiation and function. J Leukoc Biol 88, 181-188.
127. DiRaimondo TR, Klock C, Warburton R, Herrera Z, Penumatsa K, Toksoz D, Hill N, Khosla C, Fanburg B (2014) Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice. ACS Chem Biol 9, 266-275.
128. Sollid LM, Khosla C (2005) Future therapeutic options for celiac disease. Nat Clin Pract Gastroenterol Hepatol 2, 140-147.
129. Borlikova GG, Trejo M, Mably AJ, Mc Donald JM, Sala FC, Regan CM, Murphy KJ, Masliah E, Walsh DM (2013) Alzheimer brain-derived amyloid beta-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging 34, 1315-1327.
130. Duyckaerts C (2004) Looking for the link between plaques and tangles. Neurobiol Aging 25, 735-739.
131. Korponay-Szabo IR, Laurila K, Szondy Z, Halttunen T, Szalai Z, Dahlbom I, Rantala I, Kovacs JB, Fesus L, Maki M (2003) Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues. Gut 52, 199-204.
132. Nardacci R, Lo IO, Ciccosanti F, Falasca L, Addesso M, Amendola A, Antonucci G, Craxi A, Fimia GM, Iadevaia V, Melino G, Ruco L, Tocci G, Ippolito G, Piacentini M (2003) Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol 162, 1293-1303.